SEARCH

Search Details

Egawa Kiyoshi

Hokkaido University Hospital Division of Child Maternal and Female medicineLecturer

平成10年3月 北海道大学医学部医学科 卒業
平成10年5月 北海道大学医学部附属病院・医員
平成16年 4月 北海道大学大学院病態制御学専攻博士課程入学
平成18年 4月 国立病院機構静岡てんかん神経医療センター小児科
平成19年 4月 浜松医科大学神経生理学講座・特任研究員
平成20年 3月 北海道大学大学院医学研究科 病態制御学専攻博士課程 修了
平成24年 1月 Department of Neurology, Massachusetts General Hospital, MA, USA, Research fellow
平成26年 4月 北海道大学病院小児科 医員
平成28年 4月より北海道大学医学部小児科助教

令和6年4月より現在に至る

Researcher basic information

■ Degree
  • 医学博士, 北海道大学院医学研究院
■ URL
researchmap URLホームページURL■ Various IDs
Researcher number
  • 40450829
J-Global ID■ Research Keywords and Fields
Research Keyword
  • 神経生理学
  • 小児科
Research Field
  • Life Science, Clinical pharmacy, 脳神経生理
  • Life Science, Physiology, 脳神経生理
  • Life Science, Embryonic medicine and pediatrics, 小児神経学
■ Educational Organization

Research activity information

■ Awards
  • 日本てんかん学会, JUHN AND MARY WADA奨励賞
    江川 潔
■ Papers
  • A Pediatric Case of Homocystinuria Due to MTHFR Deficiency with Early Clinical Features Resembling Leigh Encephalopathy.
    Tatsunori Itabashi; Jiro Abe; Midori Nakajima; Yuki Ueda; Kiyoshi Egawa; Masayoshi Nagao; Atsuhito Takeda
    Children (Basel, Switzerland), 13, 10, 30 Sep. 2026, [International Magazine]
    English, Scientific journal, Background: Leigh encephalopathy is one of the most common phenotypes of mitochondrial diseases. It is characterized by progressive psychomotor regression, accompanied by elevated lactate/pyruvate ratios in blood and cerebrospinal fluid (CSF) and lactate on MRS, and symmetric lesions in the bilateral basal ganglia on brain MRI. A clinical diagnosis is made based on these findings and is confirmed by demonstrating mitochondrial dysfunction through genetic or enzymatic testing. However, some patients who present with clinical features of Leigh encephalopathy actually develop secondary mitochondrial dysfunction due to inborn errors of metabolism, thereby exhibiting a Leigh syndrome phenotype. Case Presentation: The patient was born at term without perinatal complications. Poor feeding was noted from two months of age, and microcephaly and hypotonia were identified at the 4-month health checkup. At 5 months, the patient was admitted for further evaluation. CSF analysis revealed an elevated lactate-to-pyruvate ratio of 21. Brain MRI demonstrated symmetrical T2-weighted hyperintensities in the bilateral basal ganglia, and MR spectroscopy detected a lactate peak in the same region. Based on clinical findings, CSF results, and MRI features, Leigh encephalopathy was suspected. At 9 months, mitochondrial DNA sequencing of skeletal muscle showed no significant mutations, and skeletal muscle biopsy revealed no findings suggestive of neuromuscular disease. At 7 years of age, two weeks after contracting COVID-19, the patient was admitted to the hospital with acute metabolic decompensation characterized by acidosis and complicated by a small intraventricular hemorrhage. Tandem mass spectrometry performed during the episode suggested homocystinuria due to MTHFR deficiency. Subsequent trio-based genetic testing revealed compound heterozygous variants in MTHFR. Measurement of MTHFR enzyme activity revealed a profound reduction, confirming the diagnosis of homocystinuria due to MTHFR deficiency. After initiation of specific metabolic therapy, including betaine, both urinary and plasma homocysteine levels decreased, and clinical symptoms improved. Conclusions: Homocystinuria due to MTHFR deficiency may cause secondary mitochondrial dysfunction, leading to a Leigh syndrome phenotype. When Leigh encephalopathy is suspected, metabolic screening should be performed to avoid missing potentially treatable diseases.
  • Combined Intracerebroventricular Enzyme Replacement and Cord Blood Transplantation in Patients with Mucopolysaccharidosis Type II Diagnosed Through Newborn Screening.
    Yuki Ueda; Shinsuke Hirabayashi; Masayuki Miura; Satoshi Yamada; Sachiko Nakakubo; Midori Nakajima; Takeru Goto; Jutaro Abe; Yukayo Terashita; Atsushi Manabe; Torayuki Okuyama; Kiyoshi Egawa
    International journal of neonatal screening, 12, 3, 26 Jun. 2026, [International Magazine]
    English, Scientific journal, Enzyme replacement therapy (ERT) for central nervous system symptoms and newborn screening (NBS) is available in Japan for patients with mucopolysaccharidosis type II (MPS II). Of 12 suspected cases identified through the NBS program, 3 patients were diagnosed with neuronopathic MPS II (2 directly from the screened cohort and 1 affected sibling). We reviewed the clinical courses of these patients, who were treated with intracerebroventricular (ICV) ERT using idursulfase beta (Hunterase®) followed by umbilical cord blood transplantation (CBT). Heparan sulfate (HS) in the cerebrospinal fluid (CSF) was longitudinally measured as a therapeutic biomarker, and developmental age was evaluated. All patients achieved successful engraftment with no severe complications, except for one patient with sinusoidal obstruction syndrome. The CSF HS concentration showed a temporary increase during the ERT discontinuation period, which can be attributed to CBT, and a subsequent reduction after the resumption of ICV-ERT. The patients exhibited age-appropriate development. The pattern of change in HS indicates the importance of continuing ICV-ERT even after hematopoietic stem cell transplantation. The study results demonstrate that the combination of ICV-ERT and CBT may yield promising outcomes in patients with neuronopathic MPS II, underscoring the importance of early intervention through NBS.
  • Region-dependent differences in tonic inhibition underlie epileptic features in Angelman syndrome model mice.
    Miho Watanabe; Takeru Goto; Ryoko Miyoshi; Sachiko Nakakubo; Yasuyoshi Hiramatsu; Midori Nakajima; Yuki Ueda; Hideaki Shiraishi; Atsushi Manabe; Prithu Mondal; Dishary Sharmin; Michael Ming Poe; James M Cook; Kiyoshi Egawa
    Epilepsia, 02 Jun. 2026, [International Magazine]
    English, Scientific journal, OBJECTIVE: Angelman syndrome (AS) is a neurodevelopmental disorder caused by loss of function of the maternally expressed UBE3A gene. Epilepsy and abnormal electroencephalographic (EEG) rhythms are key features, but their mechanisms and treatment remain unclear. Previous work showed that extrasynaptic γ-aminobutyric acid type A (GABAA) receptor-mediated tonic inhibition is reduced in cerebellar granule cells of AS model mice, contributing to motor deficits. Here, we evaluated tonic inhibition across brain regions and tested whether its dysregulation drives epilepsy, EEG abnormalities, and behavioral deficits in AS. METHODS: Tonic inhibition was measured in principal neurons of the neocortex, hippocampus, and thalamus in maternal Ube3a knockout mice. We examined the effects of MP-III-022, an α5-containing GABAA receptor-selective positive allosteric modulator, and gaboxadol, a δ-containing GABAA receptor agonist, on EEG, seizure threshold, and anxiety-like behavior. RESULTS: Tonic inhibition was reduced in cortical layer 5 and hippocampal CA1 pyramidal neurons but preserved in thalamic relay neurons. This reduction correlated with elevated GAT1 expression in the cortex and hippocampus but not the thalamus. MP-III-022 reduced abnormal slow-wave EEG activity, increased seizure thresholds, and improved anxiety-like behavior. In contrast, gaboxadol enhanced slow-wave activity and lowered seizure thresholds. SIGNIFICANCE: Deficits in tonic inhibition in AS mice are region-specific. These region-dependent differences in tonic inhibition, rather than a global loss, likely underlie EEG abnormalities and heightened seizure susceptibility. α5-containing GABAA receptors may offer a promising therapeutic target for adjunctive AS treatment.
  • Thalamic Volume Asymmetry as a Potential Predictor of Vagus Nerve Stimulation Outcomes in Refractory Epilepsy.
    Masaki Ujihara; Masahito Kawabori; Midori Nakajima; Yuki Ueda; Toru Horinouchi; Kiyoshi Egawa; Takahiro A Kato; Miki Fujimura
    Neurologia medico-chirurgica, 27 May 2026, [Domestic magazines]
    English, Scientific journal, Vagus nerve stimulation is an established treatment for refractory epilepsy, but predictors of treatment response remain unclear. Given that left-sided vagus nerve stimulation preferentially modulates the left thalamus and that epileptic networks induce thalamic structural damage, we investigated whether preoperative thalamic volume asymmetry predicts vagus nerve stimulation outcomes. This retrospective study included 17 patients with refractory epilepsy who underwent vagus nerve stimulation implantation. Patients were classified as responders (≥50% seizure reduction at 24 months, n = 9) or non-responders (n = 8). Thalamic volumes were manually segmented on preoperative T2-weighted magnetic resonance imaging by 2 blinded raters, and we used the rater-averaged values to calculate the left/right volume ratio and asymmetry index. The mean thalamic volume ratio (left/right) was significantly higher in responders than non-responders (1.00 [95% confidence interval 0.97-1.03] vs 0.96 [95% confidence interval 0.92-0.99], p = 0.027), and the asymmetry index also differed between groups (0.00 [95% confidence interval -0.015 to 0.017] vs -0.023 [95% confidence interval -0.040 to -0.006], p = 0.027). Inter-rater reliability was acceptable for absolute volumes but was lower for ratio-based asymmetry indices, suggesting that these derived metrics may be more suitable for group-level comparisons than for single-patient prediction. Epileptogenic laterality determined by electroencephalography did not predict thalamic asymmetry. Relative left thalamic volume reduction was associated with poor vagus nerve stimulation treatment response. Assessment of preoperative thalamic asymmetry on routine structural magnetic resonance imaging may represent a candidate biomarker for predicting vagus nerve stimulation efficacy, pending validation in larger cohorts.
  • Interim analysis of post-marketing surveillance study of intracerebroventricular idursulfase therapy for neuronopathic mucopolysaccharidosis type II: Safety and effectiveness in clinical practice in Japan.
    Motomichi Kosuga; Tetsumin So; Yasutsugu Chinen; Shungo Okamoto; Tokiko Fukuda; Eiichi Yamamoto; Azuma Ikari; Tadayuki Kumagai; Ikuma Musha; Yasunori Wada; Toshihiko Kakiuchi; Yuki Ueda; Kiyoshi Egawa; Yuki Yamada; Mahoko Furujo; Sumito Dateki; Yoko Nakajima; Naoko Ozawa; Torayuki Okuyama
    Molecular genetics and metabolism, 149, 1-2, 110243, 110243, 2026, [International Magazine]
    English, Scientific journal, Mucopolysaccharidosis type II (MPS II) results from iduronate-2-sulfatase (IDS) enzyme deficiency due to IDS gene mutations. Most patients with neuronopathic MPS II experience progressive neurological decline; however, effectiveness of standard treatment, intravenous idursulfase, is limited by blood-brain barrier transfer. Intracerebroventricular (ICV) idursulfase beta, approved in Japan in 2021, directly delivers idursulfase beta into cerebral ventricles. This post-marketing surveillance reports long-term effectiveness and safety of ICV idursulfase beta (30 mg every 4 weeks) in all treated patients from April 2021 through August 2024. Outcomes included cerebrospinal fluid (CSF) heparan sulfate (HS) levels (quarterly), developmental age (DA; Kyoto Scale of Psychological Development, annually), and safety. Thirty-seven Japanese male patients across 21 sites were enrolled (safety population n = 36; effectiveness population n = 35). Mean CSF HS concentrations decreased from 7.36 to 3.19 μg/mL from baseline to week 24, with reduction sustained through week 100. Patients who initiated treatment within 3 years of age had DA progression aligned with healthy cohorts, regardless of mutation type; however, those starting later had no comparable benefit. Adverse events (AEs) occurred in 20 patients (55.6%). Procedure-related serious AEs (SAEs) occurred in 2 patients (bacterial meningitis, device-related infection, pyrexia). Treatment-related AEs affected 14 patients (38.9%), mainly pyrexia (27.8%, including one SAE). One SAE (membranous glomerulonephritis) was not intervention related. No deaths, anaphylaxis, or anti-IDS antibodies in CSF were detected. ICV idursulfase beta demonstrated sustained CSF HS reduction with no new safety signals. Earlier treatment initiation (≤3 years) was associated with improved neurodevelopmental outcomes, regardless of mutation type.
  • Epileptic hub in MRI-negative focal cortical dysplasia using advanced dynamic statistical parametric mapping and magnetoencephalography.
    Yasuyoshi Hiramatsu; Midori Nakajima; Fumiya Takeuchi; Masashi Narugami; Satoshi Yamada; Sachiko Nakakubo; Takeru Goto; Shuhei Kimura; Yuki Ueda; Noriyuki Fujima; Kenji Hirata; Yuuki Ishida; Yoko Aburakawa; Keiya Iijima; Masaki Iwasaki; Rei Enatsu; Nobuhiro Mikuni; Hideaki Shiraishi; Atsushi Manabe; Kiyoshi Egawa
    Clinical neurophysiology practice, 11, 878, 887, 2026, [International Magazine]
    English, Scientific journal, OBJECTIVE: Localization of epileptogenic MRI-negative focal cortical dysplasia at the bottom of the sulcus (FCDB) is challenging. This study evaluated the utility of advanced dynamic statistical parametric mapping (AdSPM), a magnetoencephalography (MEG)-based source analysis method, for detecting epileptic MRI-negative FCDB. METHODS: We retrospectively analyzed MEG data using AdSPM in four patients with pathologically confirmed MRI-negative FCDB, whose seizure onset zones were identified by intracranial video-EEG (IVEEG). The most active area identified by the AdSPM was designated as the AdSPM spike source. We compared the spatial concordance of the AdSPM spike source, single moving dipole (SMD) findings, and 18F-FDG PET/MRI findings with seizure onset and resection areas. An additional MRI-negative patient without seizures during IVEEG monitoring was analyzed separately for concordance with the resection area. RESULTS: The AdSPM spike source localized to the seizure onset zone and was included in the resection area in all four patients with an identified seizure onset zone. SMD findings were mislocalized relative to the seizure onset zone and resection area. PET/MRI was concordant with the seizure onset zone in one of three evaluable patients and with the resection area in three of four patients. In the patient without seizures during IVEEG, AdSPM and PET/MRI were concordant with the resection area; however, the SMD findings were mislocalized. CONCLUSIONS: AdSPM noninvasively and neurophysiologically localizes epileptic MRI-negative FCDB and may provide useful information for presurgical evaluations. SIGNIFICANCE: This is the first diagnostic application of AdSPM for MRI-negative FCDB.
  • A case of pediatric insulinoma misdiagnosed as atypical epilepsy for 4 years
    Rina Takano; Nozomi Hishimura; Naoya Kaneko; Megumi Endo; Takeshi Yamaguchi; Liu Zhitong; Yasuhisa Odagawa; Shohei Honda; Tatsuhiko Kakisaka; Insu Kawahara; Daisuke Kato; Ryo Morita; Daisuke Abo; Ayumi Takayanagi; Akie Nakamura; Atsushi Manabe; Kiyoshi Egawa; Shuntaro Morikawa
    Brain and Development Case Reports, 3, 3, 100084, 100084, Elsevier BV, Sep. 2025
    Scientific journal
  • 突発性発疹に伴う脱力で発症したATP1A3遺伝子異常症、Relapsing Encephalopathy with Cerebellar Ataxia(RECA)の一例
    中久保 佐千子; 山田 聡; 平松 泰好; 後藤 健; 中島 翠; 植田 佑樹; 江川 潔; 白石 秀明
    日本遺伝カウンセリング学会誌, 46, 2, 171, 171, (一社)日本遺伝カウンセリング学会, Jul. 2025
    Japanese
  • 新規ナトリウムチャンネル拮抗薬をエトスクシミドに変更し著効した睡眠時棘徐波活性化を示すてんかん性脳症(EE-SWAS)の二例
    山田 聡; 江川 潔; 植田 佑樹; 中島 翠; 中久保 佐千子; 後藤 健; 平松 泰好; 福島 克之; 柳生 一自
    脳と発達, 57, Suppl., s240, s240, (一社)日本小児神経学会, Jun. 2025
    Japanese
  • Displacement of extracellular chloride by immobile anionic constituents of the brain's extracellular matrix.
    Kieran P Normoyle; Kyle P Lillis; Kiyoshi Egawa; Melanie A McNally; Mousumi Paulchakrabarti; Biswa P Coudhury; Lauren Lau; Fu Hung Shiu; Kevin J Staley
    The Journal of physiology, 603, 2, 353, 378, Jan. 2025, [International Magazine]
    English, Scientific journal, GABA is the primary inhibitory neurotransmitter. Membrane currents evoked by GABAA receptor activation have uniquely small driving forces: their reversal potential (EGABA) is very close to the resting membrane potential. As a consequence, GABAA currents can flow in either direction, depending on both the membrane potential and the local intra and extracellular concentrations of the primary permeant ion, chloride (Cl). Local cytoplasmic Cl concentrations vary widely because of displacement of mobile Cl ions by relatively immobile anions. Here, we use new reporters of extracellular chloride (Cl- o) to demonstrate that Cl is displaced in the extracellular space by high and spatially heterogenous concentrations of immobile anions including sulfated glycosaminoglycans (sGAGs). Cl- o varies widely, and the mean Cl- o is only half the canonical concentration (i.e. the Cl concentration in the cerebrospinal fluid). These unexpectedly low and heterogenous Cl- o domains provide a mechanism to link the varied but highly stable distribution of sGAGs and other immobile anions in the brain's extracellular space to neuronal signal processing via the effects on the amplitude and direction of GABAA transmembrane Cl currents. KEY POINTS: Extracellular chloride concentrations in the brain were measured using a new chloride-sensitive organic fluorophore and two-photon fluorescence lifetime imaging. In vivo, the extracellular chloride concentration was spatially heterogenous and only half of the cerebrospinal fluid chloride concentration Stable displacement of extracellular chloride by immobile extracellular anions was responsible for the low extracellular chloride concentration The changes in extracellular chloride were of sufficient magnitude to alter the conductance and reversal potential of GABAA chloride currents The stability of the extracellular matrix, the impact of the component immobile anions, including sulfated glycosaminoglycans on extracellular chloride concentrations, and the consequent effect on GABAA signalling suggests a previously unappreciated mechanism for modulating GABAA signalling.
  • Large-scale animal model study uncovers altered brain pH and lactate levels as a transdiagnostic endophenotype of neuropsychiatric disorders involving cognitive impairment.
    Hideo Hagihara; Hirotaka Shoji; Satoko Hattori; Giovanni Sala; Yoshihiro Takamiya; Mika Tanaka; Masafumi Ihara; Mihiro Shibutani; Izuho Hatada; Kei Hori; Mikio Hoshino; Akito Nakao; Yasuo Mori; Shigeo Okabe; Masayuki Matsushita; Anja Urbach; Yuta Katayama; Akinobu Matsumoto; Keiichi I Nakayama; Shota Katori; Takuya Sato; Takuji Iwasato; Haruko Nakamura; Yoshio Goshima; Matthieu Raveau; Tetsuya Tatsukawa; Kazuhiro Yamakawa; Noriko Takahashi; Haruo Kasai; Johji Inazawa; Ikuo Nobuhisa; Tetsushi Kagawa; Tetsuya Taga; Mohamed Darwish; Hirofumi Nishizono; Keizo Takao; Kiran Sapkota; Kazutoshi Nakazawa; Tsuyoshi Takagi; Haruki Fujisawa; Yoshihisa Sugimura; Kyosuke Yamanishi; Lakshmi Rajagopal; Nanette Deneen Hannah; Herbert Y Meltzer; Tohru Yamamoto; Shuji Wakatsuki; Toshiyuki Araki; Katsuhiko Tabuchi; Tadahiro Numakawa; Hiroshi Kunugi; Freesia L Huang; Atsuko Hayata-Takano; Hitoshi Hashimoto; Kota Tamada; Toru Takumi; Takaoki Kasahara; Tadafumi Kato; Isabella A Graef; Gerald R Crabtree; Nozomi Asaoka; Hikari Hatakama; Shuji Kaneko; Takao Kohno; Mitsuharu Hattori; Yoshio Hoshiba; Ryuhei Miyake; Kisho Obi-Nagata; Akiko Hayashi-Takagi; Léa J Becker; Ipek Yalcin; Yoko Hagino; Hiroko Kotajima-Murakami; Yuki Moriya; Kazutaka Ikeda; Hyopil Kim; Bong-Kiun Kaang; Hikari Otabi; Yuta Yoshida; Atsushi Toyoda; Noboru H Komiyama; Seth G N Grant; Michiru Ida-Eto; Masaaki Narita; Ken-Ichi Matsumoto; Emiko Okuda-Ashitaka; Iori Ohmori; Tadayuki Shimada; Kanato Yamagata; Hiroshi Ageta; Kunihiro Tsuchida; Kaoru Inokuchi; Takayuki Sassa; Akio Kihara; Motoaki Fukasawa; Nobuteru Usuda; Tayo Katano; Teruyuki Tanaka; Yoshihiro Yoshihara; Michihiro Igarashi; Takashi Hayashi; Kaori Ishikawa; Satoshi Yamamoto; Naoya Nishimura; Kazuto Nakada; Shinji Hirotsune; Kiyoshi Egawa; Kazuma Higashisaka; Yasuo Tsutsumi; Shoko Nishihara; Noriyuki Sugo; Takeshi Yagi; Naoto Ueno; Tomomi Yamamoto; Yoshihiro Kubo; Rie Ohashi; Nobuyuki Shiina; Kimiko Shimizu; Sayaka Higo-Yamamoto; Katsutaka Oishi; Hisashi Mori; Tamio Furuse; Masaru Tamura; Hisashi Shirakawa; Daiki X Sato; Yukiko U Inoue; Takayoshi Inoue; Yuriko Komine; Tetsuo Yamamori; Kenji Sakimura; Tsuyoshi Miyakawa
    eLife, 12, 26 Mar. 2024, [International Magazine]
    English, Scientific journal, Increased levels of lactate, an end-product of glycolysis, have been proposed as a potential surrogate marker for metabolic changes during neuronal excitation. These changes in lactate levels can result in decreased brain pH, which has been implicated in patients with various neuropsychiatric disorders. We previously demonstrated that such alterations are commonly observed in five mouse models of schizophrenia, bipolar disorder, and autism, suggesting a shared endophenotype among these disorders rather than mere artifacts due to medications or agonal state. However, there is still limited research on this phenomenon in animal models, leaving its generality across other disease animal models uncertain. Moreover, the association between changes in brain lactate levels and specific behavioral abnormalities remains unclear. To address these gaps, the International Brain pH Project Consortium investigated brain pH and lactate levels in 109 strains/conditions of 2294 animals with genetic and other experimental manipulations relevant to neuropsychiatric disorders. Systematic analysis revealed that decreased brain pH and increased lactate levels were common features observed in multiple models of depression, epilepsy, Alzheimer's disease, and some additional schizophrenia models. While certain autism models also exhibited decreased pH and increased lactate levels, others showed the opposite pattern, potentially reflecting subpopulations within the autism spectrum. Furthermore, utilizing large-scale behavioral test battery, a multivariate cross-validated prediction analysis demonstrated that poor working memory performance was predominantly associated with increased brain lactate levels. Importantly, this association was confirmed in an independent cohort of animal models. Collectively, these findings suggest that altered brain pH and lactate levels, which could be attributed to dysregulated excitation/inhibition balance, may serve as transdiagnostic endophenotypes of debilitating neuropsychiatric disorders characterized by cognitive impairment, irrespective of their beneficial or detrimental nature.
  • Ommaya reservoir placement using ultrasound guidance via anterior fontanelle combined with frameless electromagnetic neuronavigation in patients with mucopolysaccharidosis type 2: Case reports and review of the literature.
    Makoto Mizushima; Masahito Kawabori; Kazuyoshi Yamazaki; Kiyoshi Egawa; Miki Fujimura
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 02 Jan. 2024, [International Magazine]
    English, Scientific journal, Mucopolysaccharidosis type II (MPS II) results from the genetic deficiency of a lysosomal enzyme and is associated with central nervous system (CNS) dysfunction. In Japan, in addition to intravenous enzyme administration, intracerebroventricular enzyme delivery through the Ommaya reservoir has recently gained approval. Nevertheless, the ideal approach for safely implanting the reservoir into the narrow ventricles of infantile MPS II patients remains uncertain. In this report, we present two cases of successful reservoir placement in infantile MPS II patients using ultrasound guidance via the anterior fontanelle, coupled with flameless electromagnetic neuronavigation.
  • Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.
    Yuki Ueda; Kiyoshi Egawa; Kentaro Kawamura; Noriki Ochi; Takeru Goto; Shuhei Kimura; Masashi Narugami; Sachiko Nakakubo; Midori Nakajima; Atsushi Manabe; Hideaki Shiraishi
    Brain & development, 15 Dec. 2023, [International Magazine]
    English, Scientific journal, BACKGROUND: Most long-term affected spinal muscular atrophy (SMA) type 1 patients have severe impairment of motor function and are dependent on mechanical ventilation with tracheostomy. The efficacy and safety of nusinersen in these patients have not been established. METHODS: We retrospectively evaluated the efficacy of intrathecal nusinersen treatment in patients with SMA type 1 who continued treatment for at least 12 months. There were three patients enrolled in our study (3, 4 and 16 years of age) who had severe impairment of gross motor function without head control or the ability to roll over. All three needed mechanical ventilation with tracheostomy and tube feeding. Motor function was assessed using the Children s Hospital of Philadelphia infant test of neuromuscular disorders (CHOP-INTEND) and the caregivers' evaluations. Concurrently, we examined nerve conduction longitudinally and compared compound motor action potential (CMAP) amplitudes. RESULTS: All patients continued nusinersen administration without significant adverse events for more than three years. While CHOP-INTEND scores did not remarkably increase, according to the caregivers, all three patients had improved finger or facial muscle movements that enabled them to make their intentions understood. Some CMAPs before treatment were not identified but became traces after nusinersen administration. CONCLUSIONS: The improvement in motor function that leads to smoother communication could be a basis for continuing nusinersen treatment. Currently available motor function scorings are not efficient for assessing therapeutic interventions in SMA patients with medical care complexity. Longitudinal nerve conduction studies could be an objective indicator.
  • 【臨床てんかん学における最新の話題】小児科学領域
    中島 翠; 江川 潔; 白石 秀明
    てんかんをめぐって, 40, 27, 35, 日本てんかん学会-北海道地方会, Dec. 2023
    Japanese
  • Use of lacosamide for focal epilepsy in a child with kidney failure undergoing peritoneal dialysis.
    Yuki Ueda; Ayako Furugen; Masaki Kobayashi; Yasuyuki Sato; Yasuhiro Ueda; Asako Hayashi; Takeru Goto; Shuhei Kimura; Masashi Narugami; Sachiko Nakakubo; Midori Nakajima; Kiyoshi Egawa; Takayuki Okamoto; Atsushi Manabe; Hideaki Shiraishi
    Brain & development, 46, 2, 114, 117, 30 Oct. 2023, [International Magazine]
    English, Scientific journal, BACKGROUND: Lacosamide (LCM) has become commonly used for focal onset seizures due to its high tolerability and low drug interactions. Unlike patients on hemodialysis (HD), pharmacokinetic data and dosing recommendations for patients undergoing peritoneal dialysis (PD) are scant. CASE REPORT: A 2-year-old girl with end-stage kidney disease undergoing PD suffered prolonged focal onset seizures. The patient had congenital anomalies of the kidney and urinary tract associated with branchio-oto-renal syndrome due to an EYA1 gene mutation. She also had neurological sequelae from post-resuscitation encephalopathy at the age of one month. Antiseizure medication with few drug interactions, less impact on the neurodevelopmental state and possibility of intravenous administration was preferred. LCM met those criteria and was carefully administered. Although the patient had recurrent prolonged seizures during the titration periods, LCM could be continued without any apparent side effects. The blood levels of LCM increased linearly to the optimal level. We confirmed excretion of LCM in the PD fluid. Kidney transplantation was done three months after and her seizures were well controlled. CONCLUSIONS: LCM might be a promising option for patients undergoing PD. Due to the lower removal efficacy in PD compared with in HD, close attention should be paid to possible drug excess.
  • Transcutaneous auricular vagus nerve stimulation therapy in patients with cognitively preserved structural focal epilepsy: A case series report.
    Hideaki Shiraishi; Kiyoshi Egawa; Kaoru Murakami; Midori Nakajima; Yuki Ueda; Sachiko Nakakubo; Masashi Narugami; Shuhei Kimura; Takeru Goto; Yasuyoshi Hiramatsu; Masaaki Murakami
    Brain & development, 30 Aug. 2023, [International Magazine]
    English, OBJECTIVE: Transcutaneous auricular vagus nerve stimulation (taVNS) was performed in two patients suffering structural focal epilepsy with preserved intellectual ability to show the feasibility of taVNS for specific patient groups. CASE PRESENTATIONS: Patient 1 was a 24-year-old woman with frontal lobe epilepsy who had weekly hyperkinetic seizures despite multiple anti-seizure medications. Patient 2 was a 27-year-old woman with parietal lobe epilepsy and focal cortical dysplasia in the vicinity of the lipoma in the corpus callosum. She experienced weekly focal-impaired awareness seizures even with anti-seizure medication. taVNS was applied to the left earlobe of both patients at 1.5 mA, 25 Hz, 250 μs pulse width, and 30 s stimulation with 30 s rest for 4 h per day. Over an 8-week baseline and 20 weeks of stimulation, the rate of reduction in seizure frequency was evaluated, along with quality-of-life using the Short-Form 36-Item Health survey. RESULTS: At baseline, we measured up to 11 and 12 focal seizures per week in Patient 1 and 2, respectively, with both patients achieving seizure freedom after 4 and 20 weeks taVNS, respectively. Patient 1 and 2 were observed for 18 and 14 months, respectively, including the clinical trial and follow-up observation period. Quality-of-life ratings increased in both patients, and no significant adverse events occurred during the study period. During the maintenance period after 20 weeks, seizures remained absent in Patient 1, and seizures remained reduced in Patient 2. CONCLUSION: Our results demonstrate that taVNS may be a promising tool for structural focal epilepsy with preserved cognitive function. A multicenter double-blind clinical trial is needed to confirm the role of taVNS as an anti-seizure tool.
  • Video-based detection of epileptic spasms in West syndrome using a deep neural network: A pilot case study.
    Katsuki Eguchi; Hiroaki Yaguchi; Sachiko Nakakubo; Midori Nakajima; Yuki Ueda; Kiyoshi Egawa; Hideaki Shiraishi; Ichiro Yabe
    Journal of the neurological sciences, 449, 120671, 120671, 15 Jun. 2023, [International Magazine]
    English
  • Efficacy of sirolimus for epileptic seizures in childhood associated with focal cortical dysplasia type II
    Hideaki Shiraishi; Tsuyoshi Teramoto; Saki Yokoshiki; Jun Tohyama; Yuki Ueda; Kiyoshi Egawa; Norihiro Sato; Atsushi Manabe; Mitsuhiro Kato
    BRAIN & DEVELOPMENT, 45, 6, 343, 347, Jun. 2023
    English, Scientific journal
  • Imbalanced expression of cation-chloride cotransporters as a potential therapeutic target in an Angelman syndrome mouse model.
    Kiyoshi Egawa; Miho Watanabe; Hideaki Shiraishi; Daisuke Sato; Yukitoshi Takahashi; Saori Nishio; Atsuo Fukuda
    Scientific reports, 13, 1, 5685, 5685, 17 Apr. 2023, [International Magazine]
    English, Scientific journal, Angelman syndrome is a neurodevelopmental disorder caused by loss of function of the maternally expressed UBE3A gene. Treatments for the main manifestations, including cognitive dysfunction or epilepsy, are still under development. Recently, the Cl- importer Na+-K+-Cl- cotransporter 1 (NKCC1) and the Cl- exporter K+-Cl- cotransporter 2 (KCC2) have garnered attention as therapeutic targets for many neurological disorders. Dysregulation of neuronal intracellular Cl- concentration ([Cl-]i) is generally regarded as one of the mechanisms underlying neuronal dysfunction caused by imbalanced expression of these cation-chloride cotransporters (CCCs). Here, we analyzed the regulation of [Cl-]i and the effects of bumetanide, an NKCC1 inhibitor, in Angelman syndrome models (Ube3am-/p+ mice). We observed increased NKCC1 expression and decreased KCC2 expression in the hippocampi of Ube3am-/p+ mice. The average [Cl-]i of CA1 pyramidal neurons was not significantly different but demonstrated greater variance in Ube3am-/p+ mice. Tonic GABAA receptor-mediated Cl- conductance was reduced, which may have contributed to maintaining the normal average [Cl-]i. Bumetanide administration restores cognitive dysfunction in Ube3am-/p+ mice. Seizure susceptibility was also reduced regardless of the genotype. These results suggest that an imbalanced expression of CCCs is involved in the pathophysiological mechanism of Ube3am-/p+ mice, although the average [Cl-]i is not altered. The blockage of NKCC1 may be a potential therapeutic strategy for patients with Angelman syndrome.
  • An integrated genetic analysis of epileptogenic brain malformed lesions.
    Atsushi Fujita; Mitsuhiro Kato; Hidenori Sugano; Yasushi Iimura; Hiroharu Suzuki; Jun Tohyama; Masafumi Fukuda; Yosuke Ito; Shimpei Baba; Tohru Okanishi; Hideo Enoki; Ayataka Fujimoto; Akiyo Yamamoto; Kentaro Kawamura; Shinsuke Kato; Ryoko Honda; Tomonori Ono; Hideaki Shiraishi; Kiyoshi Egawa; Kentaro Shirai; Shinji Yamamoto; Itaru Hayakawa; Hisashi Kawawaki; Ken Saida; Naomi Tsuchida; Yuri Uchiyama; Kohei Hamanaka; Satoko Miyatake; Takeshi Mizuguchi; Mitsuko Nakashima; Hirotomo Saitsu; Noriko Miyake; Akiyoshi Kakita; Naomichi Matsumoto
    Acta neuropathologica communications, 11, 1, 33, 33, 02 Mar. 2023, [International Magazine]
    English, Scientific journal, Focal cortical dysplasia is the most common malformation during cortical development, sometimes excised by epilepsy surgery and often caused by somatic variants of the mTOR pathway genes. In this study, we performed a genetic analysis of epileptogenic brain malformed lesions from 64 patients with focal cortical dysplasia, hemimegalencephy, brain tumors, or hippocampal sclerosis. Targeted sequencing, whole-exome sequencing, and single nucleotide polymorphism microarray detected four germline and 35 somatic variants, comprising three copy number variants and 36 single nucleotide variants and indels in 37 patients. One of the somatic variants in focal cortical dysplasia type IIB was an in-frame deletion in MTOR, in which only gain-of-function missense variants have been reported. In focal cortical dysplasia type I, somatic variants of MAP2K1 and PTPN11 involved in the RAS/MAPK pathway were detected. The in-frame deletions of MTOR and MAP2K1 in this study resulted in the activation of the mTOR pathway in transiently transfected cells. In addition, the PTPN11 missense variant tended to elongate activation of the mTOR or RAS/MAPK pathway, depending on culture conditions. We demonstrate that epileptogenic brain malformed lesions except for focal cortical dysplasia type II arose from somatic variants of diverse genes but were eventually linked to the mTOR pathway.
  • Therapeutic effects of KRM-II-81, positive allosteric modulator for α2/3 subunit containing GABAA receptors, in a mouse model of Dravet syndrome.
    Sachiko Nakakubo; Yasuyoshi Hiramatsu; Takeru Goto; Syuhei Kimura; Masashi Narugami; Midori Nakajima; Yuki Ueda; Hideaki Shiraishi; Atsushi Manabe; Dishary Sharmin; James M Cook; Kiyoshi Egawa
    Frontiers in pharmacology, 14, 1273633, 1273633, 2023, [International Magazine]
    English, Scientific journal, Introduction: Dravet syndrome (DS) is an intractable epilepsy syndrome concomitant with neurodevelopmental disorder that begins in infancy. DS is dominantly caused by mutations in the SCN1A gene, which encodes the α subunit of a voltage-gated Na channel. Pre-synaptic inhibitory dysfunction is regarded as the pathophysiological mechanism, but an effective strategy for ameliorating seizures and behavioral problems is still under development. Here, we evaluated the effects of KRM-II-81, a newly developed positive allosteric modulator for α 2/3 subunit containing GABAA receptors (α2/3-GABAAR) in a mice model of DS both in vivo and at the neuronal level. Methods: We used knock-in mice carrying a heterozygous, clinically relevant SCN1A mutation (background strain: C57BL/6 J) as a model of the DS (Scn1a WT/A1783V mice), knock-in mouse strain carrying a heterozygous, clinically relevant SCN1A mutation (A1783V). Seizure threshold and locomotor activity was evaluated by using the hyperthermia-induced seizure paradigm and open filed test, respectively. Anxiety-like behavior was assessed by avoidance of the center region in locomotor activity. We estimated a sedative effect by the total distance traveled in locomotor activity and grip strength. Inhibitory post synaptic currents (IPSCs) were recorded from a hippocampal CA1 pyramidal neuron in an acutely prepared brain slice. Results: KRM-II-81 significantly increased the seizure threshold of Scn1a WT/A1783V mice in a dose-dependent manner. A low dose of KRM-II-81 specifically improved anxiety-like behavior of Scn1a WT/A1783V mice. A sedative effect was induced by relatively high dose of KRM-II-81 in Scn1a WT/A1783V mice, the dose of which was not sedative for WT mice. KRM-II-81 potentiated IPSCs by increasing its decay time kinetics. This effect was more prominent in Scn1a WT/A1783V mice. Discussion: Higher activation of α2/3-GABAAR by KRM-II-81 suggests a compensatory modification of post synaptic inhibitory function against presynaptic inhibitory dysfunction in Scn1a WT/A1783V. The increased sensitivity for KRM-II-81 may be relevant to the distinct dose-dependent effect in each paradigm of Scn1a WT/A1783V mice. Conclusion: Selective activation for α2/3-GABAAR by KRM-II-81 could be potential therapeutic strategy for treating seizures and behavioral problems in DS.
  • 異なる経過をたどった視床下部過誤腫の3例
    遠藤 愛; 高畑 明日香; 武田 賢大; 橋本 佳帆子; 兼次 洋介; 鈴木 靖人; 仲西 正憲; 中村 明枝; 江川 潔; 白水 洋史
    脳と発達, 54, 5, 343, 347, (一社)日本小児神経学会, Sep. 2022
    Japanese
  • 深層ニューラルネットワークを用いた長時間ビデオ脳波モニタリングビデオデータ中の患者発作検出の試み
    江口 克紀; 矢口 裕章; 中島 翠; 植田 佑樹; 江川 潔; 白石 秀明; 矢部 一郎
    てんかん研究, 40, 1, 86, 86, (一社)日本てんかん学会, Jun. 2022
    Japanese
  • Adrenal function during long-term ACTH therapy for patients with developmental and epileptic encephalopathy.
    Yuki Ueda; Shuta Fujishige; Takeru Goto; Shuhei Kimura; Noriko Namatame; Masashi Narugami; Sachiko Nakakubo; Midori Nakajima; Kiyoshi Egawa; Naoya Kaneko; Kanako Nakayama; Nozomi Hishimura; Takeshi Yamaguchi; Akie Nakamura; Hideaki Shiraishi
    Epilepsia open, 7, 1, 194, 200, 04 Dec. 2021, [International Magazine]
    English, Scientific journal, Some patients with developmental and epileptic encephalopathy (DEE) respond to adrenocorticotropic hormone (ACTH) therapy but relapse soon after. While long-term ACTH therapy (LT-ACTH) has been attempted for these patients, no previous studies have carefully assessed adrenal function during LT-ACTH. We evaluated the effectiveness of LT-ACTH, as well as adverse effects (AE), including their adrenal function in three DEE patients. Patients underwent a corticotropin-releasing hormone (CRH) stimulation test during LT-ACTH, and those with peak serum cortisol below 15 μg/dL were considered to be at high risk of adrenal insufficiency (AI). Two of three responded, and their life-threatening seizures with postgeneralized electroencephalogram (EEG) suppression decreased. Although no individuals had serious AE, CRH stimulation test revealed relatively weak responses, without reaching normal cortisol peak level (18 μg/dL). Hydrocortisone replacement during stress was prepared in a case with lower cortisol peak than our cutoff level. LT-ACTH could be a promising treatment option for cases of DEE that relapse soon after effective ACTH treatment. The longer duration and larger cumulative dosage in LT-ACTH than in conventional ACTH could increase the relative risk of AI. Careful evaluation with pediatric endocrinologists, including hormonal stimulation tests, might be useful for continuing this treatment safely.
  • Selective Eating in Autism Spectrum Disorder Leading to Hair Color Change.
    Yuji Maruo; Kimiaki Uetake; Kiyoshi Egawa; Hideaki Shiraishi
    Pediatric neurology, 120, 1, 2, Jul. 2021, [International Magazine]
    English
  • Flurothyl-induced seizure paradigm revealed higher seizure susceptibility in middle-aged Angelman syndrome mouse model.
    Kiyoshi Egawa; Sachiko Nakakubo; Shuhei Kimura; Takeru Goto; Atsushi Manabe; Hideaki Shiraishi
    Brain & development, 43, 4, 515, 520, Apr. 2021, [International Magazine]
    English, Scientific journal, INTRODUCTION: Epilepsy is one of the main clinical problems in Angelman syndrome (AS). Seizures typically start in early childhood then decrease or are often alleviated by young adulthood. Several studies using AS model mice showed comparable seizure susceptibility during young adulthood. In contrast, the course of epilepsy post young adulthood differs from persistently relieved to rerising among reports. To elucidate this, we evaluated the seizure susceptibility of AS model mice of two different ages. METHODS: Mice lacking maternal Ube3a gene (Ube3am-/p+) of C57BL/6 background or their littermate wild type (WT) were divided into two groups by age, 2 to 3 months (2-3 M) and 6 to 12 months (6-12 M), corresponding to adolescent to young adult aged and middle aged humans, respectively. Seizure susceptibility was evaluated by flurothyl inhalation or intraperitoneal injection of pentylenetetrazole (PTZ IP)-induced acute seizure protocol. RESULTS: In the flurothyl-induced seizure paradigm, the latency to seizure occurrence had a significant interaction with genotype and age. Post-hoc analysis revealed that the latency was significantly shorter at 6-12 M than at 2-3 M in Ube3am-/p+ mice, and in Ube3am-/p+ mice than in WT mice at 6-12 M. No significant interaction or difference was observed by PTZ IP. CONCLUSION: The flurothyl-induced seizure paradigm revealed that seizure susceptibility of Ube3am-/p+ mice increased with age, similar to clinical studies reporting the reappearance of epilepsy in older age. The flurothyl-induced seizure paradigm applied to middle-aged Ube3am-/p+ mice could be a suitable protocol for screening drugs against seizures in AS.
  • Variance in the pathophysiological impact of the hemizygosity of gamma-aminobutyric acid type A receptor subunit genes between Prader-Willi syndrome and Angelman syndrome.
    Kiyoshi Egawa; Shinji Saitoh; Naoko Asahina; Hideaki Shiraishi
    Brain & development, 43, 4, 521, 527, Apr. 2021, [International Magazine]
    English, Scientific journal, INTRODUCTION: Angelman syndrome (AS) and Prader-Willi syndrome (PWS) are neurodevelopmental disorders caused by loss of function of maternally expressed UBE3A and paternally expressed contiguous genes on chromosome 15q11-13, respectively. A majority of these syndromes suffer from a large deletion of the relevant chromosome (AS Del or PWS Del), which includes biallelically expressed gamma-aminobutyric acid type A receptor subunit (GABAaR) genes, while remaining individuals present without the deletion (AS non-Del or PWS non-Del). We previously reported that AS Del, but not AS non-Del individuals, show aberrantly desynchronized somatosensory-evoked magnetic fields (SEFs) and speculated that it might reflect GABAergic dysfunction due to the hemizygosity of GABAaR genes. To verify its pathophysiological impact on PWS and AS, we analyzed the SEFs of PWS individuals. METHOD: SEFs were recorded from eight PWS Del and two PWS non-Del individuals. The latency and strength of the first peak (N1m) were compared with those of AS Del/non-Del individuals and controls, most of which were obtained earlier. RESULTS: In contrast to AS, both PWS Del and PWS non-Del showed normal SEF waveforms. Desynchronized response with delayed N1m peak latency was exclusively indicated in AS Del. N1m strength was statistically higher in AS Del and AS non-Del, but not in PWS Del and PWS non-Del. CONCLUSIONS: Our results indicate that the pathophysiological impact of the hemizygosity of GABAaR genes is lower in PWS than AS. UBE3A deficiency and the hemizygosity of GABAaR genes could synergistically deteriorate neuronal function, resulting in aberrant SEFs in AS Del.
  • Short-latency somatosensory-evoked potentials demonstrate cortical dysfunction in patients with Angelman syndrome.
    Kiyoshi Egawa; Shinji Saitoh; Naoko Asahina; Hideaki Shiraishi
    eNeurologicalSci, 22, 100298, 100298, Mar. 2021, [International Magazine]
    English, Scientific journal, Background: Angelman syndrome (AS) is neurodevelopmental disorder, causal gene of which is maternally expressed UBE3A. A majority of patients results from the large deletion of relevant chromosome which includes GABAA receptor subunit genes (GABARs) as well as UBE3A (AS Del). We previously reported aberrantly desynchronized primary somatosensory response in AS Del by using magnetoencephalography. The purpose of this study is to estimate cortical and subcortical involvement in the deficit of primary somatosensory processing in AS. Methods: We analyzed short-latency somatosensory-evoked potentials (SSEPs) in 8 patients with AS Del. SSEPs were recorded on a 4-channel system comprising of two cortical electrodes which were placed on the frontal and centro-parietal areas. The peak and onset latency of each component were measured to compare latency and interval times. Results: The first-cortical peak latency (N20, P20), and N13-N20 peak interval times were significantly prolonged in AS Del compared to healthy controls. In contrast, there was no difference in latencies between subcortical components up to N20 onset or for N11-N20 onset interval times. Conclusion: Highly desynchronized first-cortical SSEP components and normal latencies of subcortical components indicated cortical dysfunction rather than impairment of afferent pathways in AS Del patients, which might be attributed to GABAergic dysfunction due to loss of UBE3A function and heterozygosity of GABARs.
  • Selective Eating in Autism Spectrum Disorder Leading to Kwashiorkor and Brain Edema.
    Yuji Maruo; Kiyoshi Egawa; Hidefumi Tonoki; Satoshi Terae; Yuki Ueda; Hideaki Shiraishi
    Pediatric neurology, 116, 55, 56, Mar. 2021, [International Magazine]
    English, Scientific journal
  • Reply to the letter: "Perampanel may be beneficial in leigh syndrome by its anti-oxidative but not anti-epileptic effect".
    Shuhei Kimura; Hideaki Shiraishi; Kiyoshi Egawa; Masaya Uchida; Michihiko Ueno
    Brain & development, 43, 2, 361, 362, Feb. 2021, [International Magazine]
    English
  • Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency.
    Hideaki Shiraishi; Kenji Yamada; Kiyoshi Egawa; Mika Ishige; Fumihiro Ochi; Asami Watanabe; Sanae Kawakami; Kazuyo Kuzume; Kenji Watanabe; Koji Sameshima; Kiyotaka Nakamagoe; Akira Tamaoka; Naoko Asahina; Saki Yokoshiki; Keiko Kobayashi; Takashi Miyakoshi; Koji Oba; Toshiyuki Isoe; Hiroshi Hayashi; Seiji Yamaguchi; Norihiro Sato
    Brain & development, 43, 2, 214, 219, Feb. 2021, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD) is a mitochondrial fatty acid oxidation disorder that causes episodic attacks, such as general fatigue, hypotonia, myalgia, and rhabdomyolysis accompanied by lack of energy. As yet, there are no preventative drugs for these VLCADD-associated metabolic attacks. PATIENTS AND METHODS: We conducted an open-label, non-randomized, multi-center study into the effects of bezafibrate on five patients with VLCADD. Bezafibrate was administered for 4 years, and we analyzed the number of myopathic attacks requiring hospitalization and treatment infusions. RESULTS: The number of myopathic attacks requiring infusions of 24 h or longer significantly decreased during the study period. The patients' ability to conduct everyday activities was also improved by the treatment. CONCLUSION: Our findings show the potential long-term efficacy of bezafibrate in preventing myopathic attacks for patients with VLCADD.
  • Reinterpretation of magnetic resonance imaging findings with magnetoencephalography can improve the accuracy of detecting epileptogenic cortical lesions.
    Kosuke Otsuka; Kiyoshi Egawa; Noriyuki Fujima; Kohsuke Kudo; Satoshi Terae; Midori Nakajima; Tomoshiro Ito; Kazuyori Yagyu; Hideaki Shiraishi
    Epilepsy & behavior : E&B, 114, Pt A, 107516, 107516, Jan. 2021, [International Magazine]
    English, Scientific journal, OBJECTIVE: This study examined whether the application of magnetoencephalography (MEG) to interpret magnetic resonance imaging (MRI) findings can aid the diagnosis of intractable epilepsy caused by organic brain lesions. METHODS: This study included 51 patients with epilepsy who had MEG clusters but whose initial MRI findings were interpreted as being negative for organic lesions. Three board-certified radiologists reinterpreted the MRI findings, utilizing the MEG findings as a guide. The degree to which the reinterpretation of the imaging results identified an organic lesion was rated on a 5-point scale. RESULTS: Reinterpretation of the MRI data with MEG guidance helped detect an abnormality by at least one radiologist in 18 of the 51 patients (35.2%) with symptomatic localization-related epilepsy. A surgery was performed in 7 of the 51 patients, and histopathological analysis results identified focal cortical dysplasia in 5 patients (Ia: 1, IIa: 2, unknown: 2), hippocampal sclerosis in 1 patient, and dysplastic neurons/gliosis in 1 patient. CONCLUSIONS: The results of this study highlight the potential diagnostic applications of MEG to detect organic epileptogenic lesions, particularly when radiological visualization is difficult with MRI alone.
  • Efficacy of perampanel for epileptic seizures and daily behavior in a patient with Leigh syndrome: A case report.
    Shuhei Kimura; Hideaki Shiraishi; Kiyoshi Egawa; Masaya Uchida; Michihiko Ueno
    Brain & development, 43, 1, 157, 159, Jan. 2021, [Peer-reviewed], [International Magazine]
    English, BACKGROUND: Leigh syndrome (LS) is a mitochondrial disorder that shows abnormal basal ganglia lesion and psychomotor regression. Although vitamins have been used for LS, we have not found any effective drug. CASE PRESENTATION: A 26-year-old man who showed psychomotor delay and short stature at the age of 1 year was diagnosed with LS according to the results of cerebrospinal fluid and high signal intensity in the bilateral striatum on T2-weighted magnetic resonance imaging. He demonstrated psychomotor delay and breathing disorders, but the progression was very slow. His symptoms suddenly worsened at the age of 24 years after acute epididymitis. He showed epileptic seizures simultaneously and his activities of daily living (ADL) significantly worsened. Several antiepileptic drugs were ineffective, but his seizures were suppressed by a low dose of perampanel and his ADL improved. CONCLUSION AND DISCUSSION: Our case showed that low-dose perampanel could be a drug for epileptic seizures and improvement of ADL in patients with LS.
  • アンジェルマン症候群の病態生理と治療に関する最近の話題
    江川 潔; 白石 秀明
    てんかんをめぐって, 38, 11, 19, 日本てんかん学会-北海道地方会, Dec. 2020
    Japanese, アンジェルマン症候群は、母性発現遺伝子UBE3Aを原因因子とする遺伝性疾患で、精神運動発達遅滞、言語障害、運動機能障害、特徴的な顔貌を主要症状とする。アンジェルマン症候群を発症する遺伝的メカニズムを紹介し、その病態生理の一つとして、GABA抑制系機能障害に関する著者らの研究を紹介した。また、アンジェルマン症候群のてんかんと治療に関する最近のトピックスを紹介した。
  • アンジェルマン症候群モデルマウスにおける脳皮質GABA持続抑制減弱と神経機能障害
    江川 潔; 白石 秀明; Cook James
    てんかん研究, 38, 1, 103, 104, (一社)日本てんかん学会, Jun. 2020
    Japanese
  • Perampanel for nonepileptic myoclonus in Angelman syndrome.
    Osamu Kawano; Kiyoshi Egawa; Hideaki Shiraishi
    Brain & development, 42, 5, 389, 392, May 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Angelman syndrome (AS) is a neurodegenerative disorder caused by functional loss of the maternal ubiquitin-protein ligase 3A gene. Nonepileptic myoclonus, also described as tremulous movement, often occurs during puberty and increases in adulthood. The involuntary movement in AS has not been defined patho-physiologically and the drugs used such as levetiracetam and piracetam are not always effective. Recently, the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonist, perampanel (PER), was used to alleviate myoclonus in progressive myoclonus epilepsy. Herein, we tested the efficacy of PER for nonepileptic myoclonus. METHODS AND RESULTS: Four patients with AS, aged from 20 to 40 years at the beginning of treatment, were enrolled in our study. All patients reported disruption to their daily lives from the myoclonus movement. They experienced mild to moderate improvement with the starting dose of 2 mg. The dose was increased to 4 mg in one patient to achieve sufficient efficacy, while two had their dose reduced to 1 mg due to dizziness or possible exacerbation of myoclonus. The last patient continued to take the starting dose. Follow-up over 16-20 months revealed a significant reduction in the severity of nonepileptic myoclonus in all patients. CONCLUSION: Our study suggests that PER could be one of the promising drugs for nonepileptic myoclonus in AS.
  • A neonatal case of spinal muscular atrophy type I treated with nusinersen from 55 days of age
    Eri Nishino; Noriko Namatame; Osamu Kawano; Kiyoshi Egawa; Takashi Ogasawara; Makoto Kaneda; Hideaki Shiraishi
    No To Hattatsu, 52, 1, 38, 40, Japanese Society of Child Neurology, 2020
    Japanese, Scientific journal
  • 日齢55よりnusinersenによる治療を開始した脊髄性筋萎縮症I型の1例
    西野 瑛理; 生田目 紀子; 河野 修; 江川 潔; 小笠原 卓; 金田 眞; 白石 秀明
    脳と発達, 52, 1, 38, 40, (一社)日本小児神経学会, Jan. 2020
    Japanese
  • アンジェルマン症候群モデルマウスにおける脳波・発作閾値の検討
    江川 潔; 白石 秀明
    てんかんをめぐって, 37, 49, 54, 日本てんかん学会-北海道地方会, Dec. 2019
    Japanese, アンジェルマン症候群(AS)は、母性発現遺伝子UBE3Aを原因遺伝子とする疾患で、その約8割に癲癇を合併するとされている。今回、ASモデルマウス(Ube3aを機能欠失させたC57/BL6系マウス)における癲癇発作の客観的評価を試みた。頭蓋内電極を埋め込み、24時間ビデオ脳波記録を行ったところ、癲癇性放電と徐波成分の増強が認められたものの、自発癲癇発作は認められず、自発発作の頻度による癲癇の評価は困難と考えられた。次にGABA受容体拮抗薬Pentylenetetrazolを腹腔内投与し、痙攣発作の観察を30分間行ったが、個体毎のバラツキが大きく、野生型マウス(WT)との有意差は認められなかった。そこで、揮発性のGABA受容体拮抗薬Fluorothylを密閉したチャンバー内に持続注入し、マウスが揮発ガスを吸入し痙攣に至るまでの潜時を調べることで発作閾値を評価した。結果、ASモデルマウスの発作閾値はWTに比べて有意に低く、本法はASモデルマウスにおける発作閾値評価法として優れていることが示唆された。
  • Down症候群の発達と療育 合併症の有無による検討
    生田目 紀子; 江川 潔; 須藤 章; 石川 丹
    脳と発達, 51, 6, 373, 379, (一社)日本小児神経学会, Nov. 2019
    Japanese
  • Diverse Actions of Astrocytes in GABAergic Signaling.
    Masaru Ishibashi; Kiyoshi Egawa; Atsuo Fukuda
    International journal of molecular sciences, 20, 12, 18 Jun. 2019, [Peer-reviewed], [International Magazine]
    English, Scientific journal, An imbalance of excitatory and inhibitory neurotransmission leading to over excitation plays a crucial role in generating seizures, while enhancing GABAergic mechanisms are critical in terminating seizures. In recent years, it has been reported in many studies that astrocytes are deeply involved in synaptic transmission. Astrocytes form a critical component of the "tripartite" synapses by wrapping around the pre- and post-synaptic elements. From this location, astrocytes are known to greatly influence the dynamics of ions and transmitters in the synaptic cleft. Despite recent extensive research on excitatory tripartite synapses, inhibitory tripartite synapses have received less attention, even though they influence inhibitory synaptic transmission by affecting chloride and GABA concentration dynamics. In this review, we will discuss the diverse actions of astrocytic chloride and GABA homeostasis at GABAergic tripartite synapses. We will then consider the pathophysiological impacts of disturbed GABA homeostasis at the tripartite synapse.
  • Psychomotor development and rehabilitation in down syndrome: Investigations with complications
    Noriko Namatame; Kiyoshi Egawa; Akira Sudo; Akashi Ishikawa
    No To Hattatsu, 51, 6, 373, 379, Japanese Society of Child Neurology, 2019
    Japanese, Scientific journal
  • Long-term follow up of an adult with alternating hemiplegia of childhood and a p.Gly755Ser mutation in the ATP1A3 gene.
    Tomoshiro Ito; Masashi Narugami; Kiyoshi Egawa; Hiroyuki Yamamoto; Naoko Asahina; Shinobu Kohsaka; Atsushi Ishii; Shinichi Hirose; Hideaki Shiraishi
    Brain & development, 40, 3, 226, 228, Mar. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Alternating hemiplegia of childhood (AHC) is a rare neurological disease mainly caused by mutations in the ATP1A3 gene and showing varied clinical severity according to genotype. Patients with a p.Gly755Ser (p.G755S) mutation, one of minor genotypes for AHC, were recently described as having a mild phenotype, although their long-term outcomes are still unclear due to the lack of long-term follow up. Here, we demonstrate the full clinical course of a 43-year-old female AHC patient with p.G755S mutation. Although her motor dysfunction had been relatively mild into her 30 s, she showed a subsequent severe aggravation of symptoms that left her bedridden, concomitant with a recent recurrence of seizure status. The seizures were refractory to anti-epileptic drugs, but administration of flunarizine improved seizures and the paralysis. Our case suggests that the phenotype of AHC with p.G755S mutation is not necessarily mild, despite such a presentation during the patient's younger years.
  • Minimum Norm Estimateを用いた広汎性脳磁場解析
    田中 雅大; 山本 啓之; 河野 修; 伊藤 智城; 江川 潔; 香坂 忍; 朝比奈 直子; 江夏 怜; 越智 さと子; 三國 信啓; 白石 秀明
    てんかん研究, 35, 1, 74, 74, (一社)日本てんかん学会, Jun. 2017
    Japanese
  • Chloride Dysregulation, Seizures, and Cerebral Edema: A Relationship with Therapeutic Potential.
    Joseph Glykys; Volodymyr Dzhala; Kiyoshi Egawa; Kristopher T Kahle; Eric Delpire; Kevin Staley
    Trends in neurosciences, 40, 5, 276, 294, May 2017, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA).
    Hideaki Shiraishi; Kiyoshi Egawa; Tomoshiro Ito; Osamu Kawano; Naoko Asahina; Shinobu Kohsaka
    Epilepsy & behavior case reports, 8, 44, 46, Elsevier Inc., 2017, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • てんかん脳磁図の最前線 発作時脳磁図のdynamic statistical parametric mapping(dSPM)解析
    山本 啓之; 柳生 一自; 鳴神 雅史; 伊藤 智城; 江川 潔; 眞鍋 智代; 高橋 香代子; 中根 進児; 白石 秀明
    日本生体磁気学会誌, 29, 1, 12, 13, 日本生体磁気学会, Jun. 2016
    Japanese
  • 器質的疾患により思春期早発症を来した2例
    山口 健史; 森川 俊太郎; 石津 桂; 江川 潔; 白石 秀明; 田島 敏広; 有賀 正
    日本小児科学会雑誌, 120, 2, 346, 346, (公社)日本小児科学会, Feb. 2016
    Japanese
  • The presence of short and sharp MEG spikes implies focal cortical dysplasia.
    Yuki Ueda; Kiyoshi Egawa; Tomoshiro Ito; Fumiya Takeuchi; Midori Nakajima; Kosuke Otsuka; Naoko Asahina; Kayoko Takahashi; Shingo Nakane; Shinobu Kohsaka; Hideaki Shiraishi
    Epilepsy research, 114, 141, 6, Aug. 2015, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • 【神経症候群(第2版)-その他の神経疾患を含めて-】てんかん症候群 その他の重要な病態 Angelman症候群
    白石 秀明; 江川 潔; 細木 華奈
    日本臨床, 別冊, 神経症候群VI, 436, 440, (株)日本臨床社, Dec. 2014
    Japanese
  • Response to Comments on "Local impermeant anions establish the neuronal chloride concentration"
    J. Glykys; V. Dzhala; K. Egawa; T. Balena; Y. Saponjian; K. V. Kuchibhotla; B. J. Bacskai; K. T. Kahle; T. Zeuthen; K. J. Staley
    SCIENCE, 345, 6201, Sep. 2014, [Peer-reviewed]
    English
  • Local Impermeant Anions Establish the Neuronal Chloride Concentration
    J. Glykys; V. Dzhala; K. Egawa; T. Balena; Y. Saponjian; K. V. Kuchibhotla; B. J. Bacskai; K. T. Kahle; T. Zeuthen; K. J. Staley
    SCIENCE, 343, 6171, 670, 675, Feb. 2014, [Peer-reviewed]
    English, Scientific journal
  • Cl⁻ homeodynamics in gap junction-coupled astrocytic networks on activation of GABAergic synapses.
    Kiyoshi Egawa; Junko Yamada; Tomonori Furukawa; Yuchio Yanagawa; Atsuo Fukuda
    The Journal of physiology, 591, 16, 3901, 17, 15 Aug. 2013, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • Deteriorated degradation of GAT1 by Ube3 a deficiency causes a decrement of tonic inhibition in cerebellar granule cells and a cerebellar ataxia
    Fukuda Atsuo; Egawa Kiyoshi; Kitagawa Kyoko; Takayama Masakazu; Takayama Chitoshi; Saitoh Shinji; Kishino Tatsuya; Kitagawa Masatoshi
    JOURNAL OF PHYSIOLOGICAL SCIENCES, 63, S125, 2013, [Peer-reviewed]
  • Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models.
    Kiyoshi Egawa; Atsuo Fukuda
    Frontiers in neural circuits, 7, 170, 170, 2013, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome.
    Kiyoshi Egawa; Kyoko Kitagawa; Koichi Inoue; Masakazu Takayama; Chitoshi Takayama; Shinji Saitoh; Tatsuya Kishino; Masatoshi Kitagawa; Atsuo Fukuda
    Science translational medicine, 4, 163, 163ra157, 05 Dec. 2012, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • GABAergic dysfunction in Ube3a deficient mice, models of Angelman syndrome
    Egawa Kiyoshi; Inoue Koichi; Saitoh Shinji; Kishino Tatsuya; Fukuda Atsuo
    Neuroscience Research, 71, e400, Elsevier, 2011, [Peer-reviewed]
  • Dominant-negative mutations in alpha-II spectrin cause West syndrome with severe cerebral hypomyelination, spastic quadriplegia, and developmental delay.
    Hirotomo Saitsu; Jun Tohyama; Tatsuro Kumada; Kiyoshi Egawa; Keisuke Hamada; Ippei Okada; Takeshi Mizuguchi; Hitoshi Osaka; Rie Miyata; Tomonori Furukawa; Kazuhiro Haginoya; Hideki Hoshino; Tomohide Goto; Yasuo Hachiya; Takanori Yamagata; Shinji Saitoh; Toshiro Nagai; Kiyomi Nishiyama; Akira Nishimura; Noriko Miyake; Masayuki Komada; Kenji Hayashi; Syu-Ichi Hirai; Kazuhiro Ogata; Mitsuhiro Kato; Atsuo Fukuda; Naomichi Matsumoto
    American journal of human genetics, 86, 6, 881, 91, 11 Jun. 2010, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • Electroclinical features of epilepsy in patients with juvenile type dentatorubral-pallidoluysian atrophy.
    Kiyoshi Egawa; Yukitoshi Takahashi; Yuko Kubota; Hideki Kubota; Yushi Inoue; Takeki Fujiwara; Osamu Onodera
    Epilepsia, 49, 12, 2041, 9, Dec. 2008, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • [(11)C]flumazenil positron emission tomography analyses of brain gamma-aminobutyric acid type A receptors in Angelman syndrome.
    Naoko Asahina; Tohru Shiga; Kiyoshi Egawa; Hideaki Shiraishi; Shinobu Kohsaka; Shinji Saitoh
    The Journal of pediatrics, 152, 4, 546, 9, Apr. 2008, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • Aberrant somatosensory-evoked responses imply GABAergic dysfunction in Angelman syndrome.
    Kiyoshi Egawa; Naoko Asahina; Hideaki Shiraishi; Kyousuke Kamada; Fumiya Takeuchi; Shingo Nakane; Akira Sudo; Shinobu Kohsaka; Shinji Saitoh
    NeuroImage, 39, 2, 593, 9, 15 Jan. 2008, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • Graded Magnetoencephalographic Analysis for Patients with Epilepsy : For Universal Application for Every Patient with Epilepsy
    SHIRAISHI Hideaki; TAKEUCHI Fumiya; EGAWA Kiyoshi; SUEDA Keitaro; ASAHINA Naoko; KOHSAKA Shinobu; NAKANE Shingo; SAITOH Shinji
    CI研究 : progress in computed imaging, 29, 1, 43, 49, 日本脳神経CI学会, 30 Jun. 2007
    Japanese, 小児のてんかん109症例を対象に、妥当性のある異常磁場活動に関する情報を得るための脳磁場(MEG)測定法を検討した。単一双極子法では、83症例でてんかん原性領域を特定でき、電流源が単一脳回に局在し、等価電流双極子(ECD)の局在に集積傾向を示した。残り26症例にdynamic statistical parametric mappingを用いた解析を行ったところ、16例で臨床発作対応の得られる磁場分布の表現が可能であった。これらの解析によっても解が得られなかった症候性局在関連てんかん10例に短時間フーリエ変換を用いた周波数解析を行ったところ、最頻出現周波数帯域の局在が求められ、臨床発作対応の得られる磁場分布であった。考え得る全てのてんかん性異常磁場活動の評価は、これらの捕捉された脳磁場波形を適切に適応することにより可能であると考えられた。
  • Long-term sequential magnetoencephalographic analyses for patients with atypical benign partial epilepsy in childhood
    Hideaki Shiraishi; Kiyoshi Egawa; Naoko Asahina; Shinji Nakane; Yasuyo Udo; Akira Satake; Shinobu Kohsaka; Shinji Saitoh
    International Congress Series, 1300, 689, 692, Jun. 2007, [Peer-reviewed]
    English, Scientific journal
  • 【抗てんかん薬による治療 新たな動向と展望】自己免疫反応から見たてんかん予防・治療の可能性
    高橋 幸利; 西村 成子; 角替 央野; 大谷 英之; 四家 達彦; 二階堂 弘輝; 小田 望; 江川 潔; 池田 浩子
    臨床精神薬理, 10, 4, 607, 616, (株)星和書店, Apr. 2007
    Japanese
  • てんかん症例における律動波に対する脳磁図解析の試み
    白石 秀明; 竹内 文也; 江川 潔; 末田 慶太朗; 朝比奈 直子; 香坂 忍; 中根 進児; 斉藤 伸治
    てんかんをめぐって, XXVI, 73, 73, 日本てんかん学会-北海道地方会, Mar. 2007
    Japanese
  • てんかん症例における脳磁律動波に対する周波数解析の試み
    白石 秀明; 竹内 文也; 江川 潔; 末田 慶太朗; 朝比奈 直子; 香坂 忍; 中根 進児; 斉藤 伸治
    てんかんをめぐって, XXVI, 31, 36, 日本てんかん学会-北海道地方会, Mar. 2007
    Japanese, 15歳女児。10歳時に初発したが顕在化せず、12歳時に発作が出現し抗てんかん薬治療を開始したが発作は持続し、14歳時のMRIで左後頭葉・頭頂葉に限局性病変を認め、Dysembryoplastic neuroepithelial tumor(DNT)と診断した。発作間歇時SPECTで腫瘍像と一致した部位に集積欠損領域を認め、左前頭葉集積は右側より低下していた。頭皮上脳波・脳磁図は左半球性に出現する磁場活動上の多棘波に対応し、周波数解析では棘律動が腫瘍部分周辺および腫瘍前方の前頭葉領域に拡延して出現した。腫瘍摘出術は皮質脳波所見の腫瘍縁より一脳回広く脳回切除を施行し、病理所見はDNTであった。術後皮質脳波で前頭葉方向の拡延する棘律動は残存したが術後1年発作症状は認めていない。以上より、律動性棘波は脳磁場計測においても位相、周波数ともにほぼ相同な波形を示し周波数解析法のみが解析可能な方法と考えられた。また、基礎活動としての律動波に対しても磁場解析の可能性が示唆された。
  • てんかん症例に対する脳磁場解析の段階的手法 全てのてんかん症例に対する適応を目指して
    白石 秀明; 竹内 文也; 中根 進児; 末田 慶太朗; 江川 潔; 朝比奈 直子; 香坂 忍; 齋藤 伸治
    臨床神経生理学, 34, 5, 448, 449, (一社)日本臨床神経生理学会, Oct. 2006
    Japanese
  • けいれん性疾患およびてんかんの治療の最近の進歩 熱性けいれんおよび下痢に伴うけいれんの治療
    白石 秀明; 江川 潔; 朝比奈 直子; 香坂 忍; 斉藤 伸治
    脳と発達, 38, 5, 391, 391, (一社)日本小児神経学会, Sep. 2006
    Japanese
  • 乳児期に誤ってPrader-Willi症候群と診断されたAngelman症候群の4例
    斉藤 伸治; 江川 潔; 朝比奈 直子; 白石 秀明
    脳と発達, 38, 5, 392, 392, (一社)日本小児神経学会, Sep. 2006
    Japanese
  • 【てんかんの研究と治療 最近の進歩】てんかんと自己免疫
    高橋 幸利; 西村 成子; 角替 央野; 大谷 英之; 四家 達彦; 二階堂 弘輝; 小田 望; 江川 潔
    最新精神医学, 11, 4, 349, 354, (株)世論時報社, Jul. 2006
    Japanese
  • 肝膿瘍を契機に診断がついた慢性肉芽腫症の1例
    小林 穂高; 江川 潔; 藤田 祥二; 阿部 修司; 遠藤 満智子
    函館五稜郭病院医誌, 14, 20, 23, 函館五稜郭病院, Apr. 2006
    Japanese, 4歳4ヵ月男児.正常分娩で正常に出産したが生後6ヵ月から肛門周囲膿瘍,中耳炎,歯肉炎,口内炎,皮膚感染,麦粒腫などの細菌感染を反復した既往があった.腹部の圧痛の出現に続いて発熱を認め,腹部腫瘤が認められたことから入院となった.父親や姉に易感染性を疑う既往はなかったが,母親は小児期から傷が化膿しやすかった.腹部腫瘤は肝臓腫大であり,腹部CTにて肝膿瘍と診断し,肉芽腫性病変と考えられた.好中球機能検査の結果,貪食能は98.6%と正常であったが,殺菌能は16.7%と低下しており,慢性肉芽腫症と診断した
  • 脊髄動静脈奇形を原因とするクモ膜下出血の1乳児例
    佐藤 泰征; 江川 潔; 朝比奈 直子; 白石 秀明; 斉藤 伸治; 有賀 正
    日本小児科学会雑誌, 110, 4, 593, 593, (公社)日本小児科学会, Apr. 2006
    Japanese
  • Angelman症候群の再発危険率と遺伝カウンセリング
    斉藤 伸治; 江川 潔; 朝比奈 直子; 白石 秀明; 須藤 章
    北海道医学雑誌, 81, 2, 172, 173, 北海道医学会, Mar. 2006
    Japanese
  • Panayiotopoulos症候群の長期経過と治療効果
    須藤 章; 佐竹 明; 梶井 直文; 江川 潔; 朝比奈 直子; 白石 秀明; 石川 信義; 斉藤 伸治
    てんかんをめぐって, XXV, 26, 35, 日本てんかん学会-北海道地方会, Mar. 2006
    Japanese, Panayiotopoulos症候群と診断確実な症例の全経過の臨床的特徴を詳細に明らかにするため,けいれん性疾患で2年以上脳波フォローができた440例中,条件を全て満たし,抗てんかん薬中止後2年以上観察できた17例を対象として診療録をもとに後方視的に検討した.熱性けいれんの既往を6例に認めた.両親または兄弟が熱性けいれんまたはてんかんとされた家族歴を有するものを6例で認めた.発作時の年齢は,4歳をピークとして年齢とともに発作症例が減少し,10歳以後の発作症例はなかった.抗てんかん薬使用前後の発作回数は,治療前後で有意差なく,17例中12例で投薬後にも再発した.17例全例で投薬終了後2年間経過観察したが,発作の再発例はなく,脳波異常の再現もなかった
  • 非定型良性小児部分てんかん症例の経時的変化 脳磁図所見,治療経過を中心に
    白石 秀明; 江川 潔; 朝比奈 直子; 須藤 章; 香坂 忍; 斉藤 伸治; 中根 進児; 有働 康代
    てんかんをめぐって, XXV, 65, 66, 日本てんかん学会-北海道地方会, Mar. 2006
    Japanese
  • Dynamic statistical parametric mapping for analyzing the magnetoencephalographic epileptiform activity in patients with epilepsy.
    Hideaki Shiraishi; Steven M Stufflebeam; Susanne Knake; Seppo P Ahlfors; Akira Sudo; Naoko Asahina; Kiyoshi Egawa; Keisaku Hatanaka; Shinobu Kohsaka; Shinji Saitoh; P Ellen Grant; Anders M Dale; Eric Halgren
    Journal of child neurology, 20, 4, 363, 9, Apr. 2005, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • Really sterile pyuria with Kawasaki disease?
    Nobuko Shiono; Yasutsugu Koga; Hironobu Ito; Kiyoshi Egawa; Satoru Ono; Noritomo Itami
    Pediatric nephrology (Berlin, Germany), 19, 1, 124, 124, Jan. 2004, [Peer-reviewed], [International Magazine]
    English
■ Other Activities and Achievements
■ Books and other publications
  • The Causes of Epilepsy, 2nd edition
    Kiyoshi Egawa, Chapter 46. Dentatorubral-Pallidoluysian atrophy (DRPLA).
    Cambridge Press, Dec. 2018
■ Syllabus
  • 医学総論, 2024年, 博士後期課程, 医学研究科
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
  • 発達障害学, 2024年, 学士課程, 医学部
  • 小児健康障害論, 2024年, 学士課程, 医学部
  • 小児科学・小児外科学, 2024年, 学士課程, 医学部
■ Research Themes
  • 遺伝性自閉スペクトラム症における肥満の病態生理-疾患モデルマウスによる解明
    科学研究費助成事業
    01 Apr. 2025 - 31 Mar. 2028
    江川 潔
    日本学術振興会, 基盤研究(C), 北海道大学, 25K11075
  • ドラベ症候群におけるα2サブユニット選択的GABA(A)受容体賦活薬の有効性検証
    科学研究費助成事業 基盤研究(C)
    01 Apr. 2022 - 31 Mar. 2025
    江川 潔
    日本学術振興会, 基盤研究(C), 北海道大学, 22K07930
  • なぜ概日リズム中枢はGABA作動性神経細胞から構成されるのか?
    科学研究費助成事業 基盤研究(B)
    01 Apr. 2020 - 31 Mar. 2024
    榎木 亮介; 江川 潔
    本研究課題では、哺乳類の概日時計中枢である視床下部の視交叉上核が何故GABA作動性神経細胞で構成されるのかを、光イメージング技術を駆使して解明することを目指している。本年度は特に、神経細胞のGABA応答性(脱分極-過分極)を決定するクロライドイオンに着目して研究を行った。アデノ随伴ウイルスを用いて遺伝子コード型クロライドを視交叉上核の神経細胞に感染発現させ、視交叉上核におけるプローブの発現パターンと機能動作の確認を行ったところ、プローブは視交叉上核の全領域において発現しており、その蛍光輝度は細胞内クロライド濃度の操作に伴い予測通りに変化することを確認した。蛍光-クロライド濃度の検量カーブを作成して細胞内クロライド濃度を計算し、パッチクランプ計測により報告されている従来のクロライド濃度とほぼ一致した。さらに長期蛍光イメージング顕微鏡システムにより数日間のタイムラプス計測を行ったところ、クロライドイオン濃度の24時間のリズムを細胞ネットワークレベルで観察した。リズム解析プログラムによりリズムの振幅、最低値、位相などを解析したところ、神経細胞ネットワークにおける特徴的な部位差とリズム位相パターンがあることを見いだした。またクロライドイオンとカルシウムイオンの同時イメージング計測を行い、既知のカルシウムリズムと比較することで"概日クロライドリズム"の位相を決定した。
    日本学術振興会, 基盤研究(B), 大学共同利用機関法人自然科学研究機構(新分野創成センター、アストロバイオロジーセンター、生命創成探究, 20H03425
  • GABA持続抑制不全の多様性がもたらすアンジェルマン症候群の病態解明と治療法開発
    科学研究費助成事業 基盤研究B
    2018 - 2021
    江川 潔
    Principal investigator, Competitive research funding
  • アンジェルマン症候群におけるてんかんの病態生理解明と治療法 の開発
    研究助成
    Apr. 2019 - Mar. 2020
    公益財団法人てんかん治療研究振興財団, 基礎, 北海道大学院医学研究院小児科, Principal investigator, Competitive research funding
  • 細胞発振現象と集団発振のモーダルシフト
    科学研究費助成事業 新学術領域
    2015 - 2020
    福田敦夫
    Competitive research funding
  • Pathophysiological impact of diverse deregulation of tonic inhibition in Angelman syndrome
    Research grant award
    Jan. 2017 - Dec. 2018
    Kiyoshi Egawa
    Angelman syndrome foundation, Principal investigator, Competitive research funding
  • 自閉症スペクトラム、アンジェルマン症候群患者 iPS 細胞を用いた病態解析と治療法開発
    母子健康協会
    2017 - 2018
    江川 潔
    Principal investigator, Competitive research funding
  • 自閉症スペクトラム、アンジェルマン症候群の認知機能障害メカニズムと治療法の探索
    小児医学研究振興財団
    2017 - 2018
    江川 潔
    Principal investigator, Competitive research funding
  • アンジェルマン症候群の運動機能障害に対するモデルマウスおよびiPS細胞を用いた治療戦略の探索
    中冨健康科学振興財団
    2016 - 2018
    江川 潔
    Principal investigator, Competitive research funding
  • 自閉症スペクトラムを示すアンジェルマン症候群の認知機能障害メカニズムと治療法の探索
    武田科学振興財団
    2016 - 2018
    江川 潔
    Principal investigator, Competitive research funding
  • アンジェルマン症候群における認知記憶機能障害のメカニズムと治療法の探索
    科学研究費助成事業 基盤研究C
    2015 - 2018
    江川 潔
    Principal investigator, Competitive research funding
  • 自閉症スペクトラム障害アンジェルマン症候群におけるケトン食糧法の有用性
    ひと・健康・未来研究財団
    2015 - 2016
    江川 潔
    Principal investigator, Competitive research funding
  • Perturbation of developmental Cl^-homeodynamics may underlie fetal and neonatal brain disorders
    Grants-in-Aid for Scientific Research
    2011 - 2011
    FUKUDA Atsuo; INOUE Koichi; EGAWA Kiyoshi; HATA Kenichiro
    The most major inhibitory neurotransmitter, GABA, induces synaptic inhibition in the adult brain. In immature neurons, however,[ Cl^-]_i is high due to balance of Cl^-transporters, promoting depolarizing GABA action by efflux of Cl^-along with its electrical gradient. Thus GABA evokes excitation and/or non-synaptic tonic depolarization in immature brain. Such multimodal GABA actions during development are necessary for neurogenesis, differentiation, migration, and synaptogenesis. Therfore, perturbation of the developmental Cl^-homeodynamics may underlie fetal and neonatal brain disorders. By using various pathological model mice, we have studied how Cl^-homeodynamics work in pathogenesis of fetal and neonatal disorders of cortical development.
    Japan Society for the Promotion of Science, Grant-in-Aid for Challenging Exploratory Research, Hamamatsu University School of Medicine, 23659535
  • アンジェルマン症候群モデルマウスにおける小脳機能障害の電気生理学的検討
    科学研究費助成事業 若手B
    2011 - 2011
    江川 潔
    ASにおける小脳機能障害メカニズムの解明を目的として、母性Ube3a欠失マウス(以下ASマウス)小脳急性スライスを用いた電気生理学的検討を行った。予備実験において、抑制性シナプスの抑制力を規定するクロライドトランスポーターKCC2の発現が増大していたことから、小脳顆粒細胞プルキンエ細胞におけるGABAシグナルの抑制力を検討したが、優位な差を認めなかった。しかしながら、シナプス外GABA_A受容体を介する持続抑制(tonic inhibition)を検討したところ、ASモデルマウスでtonic inhibitionが約1/3に低下していることが明らかになった。薬理学的検討,および免疫生化学的検討から、tonic inhibition低下の原因として、シナプス間隙よりGABAの再取り込みを担うGABA transporter 1 (GAT1)の機能亢進がtonic inhibition減少の原因であること、さらにGAT1とUBE3AのHEK細胞における強制発現系および小脳ライセートを用いたdegradation asseyによる検討から、GAT1がUBE3Aのsbstrate存在することを明らかにした。シナプス外GABA_A受容体選択的アゴニストTHIPの投与により、ASの小脳機能不全がin vitro, in vivoともに改善されたことから、GAT1 degradationの機能不全によりGABA抑制,特にtonic inhibitionの低下がAS小脳機能障害のメカニズムとして重要であることが明らかになった。
    本研究の成果として、これまでまったくメカニズムが不明であったASの小脳機能障害について解明をおこない、全く新しい治療戦略の可能性を提示した。小脳顆粒細胞のtonic inhibitionが、病態生理として意味をもつことを疾患モデルマウスとして初めて示した。更にGABA抑制機能の調節因子として注目されるGAT1の分解,ターンオーバーについて新たな知見を加えるとともに、GABA抑制系にかかわる膜蛋白がコビキチン-プロテアソーム系により機能制御をうけることを初めて示し、新たなシナプス可塑の形を提示することで、臨床医学のみならず、基礎神経科学の分野にも一定の貢献を与えるものとなった。
    日本学術振興会, 若手研究(B), 浜松医科大学, Principal investigator, Competitive research funding, 23791166